TO THE Orer Pharmaceutical Import Profile — Gambia (DGFT 2022–2026)

Name: TO THE Orer Pharmaceutical Import Records from India — 2 Products, $400.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

TO THE Orer — Pharmaceutical Importer Profile (2026) | 2 Products, $400.0K Trade | TransData Nexus

TO THE Orer

Pharmaceutical Importer · Gambia · Antimalarial & Antiparasitic Focus · $400.0K Total Trade · DGFT Verified

TO THE Orer is a pharmaceutical importer based in Gambia with a total trade value of $400.0K across 2 products in 1 therapeutic categories. Based on 8 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. TO THE Orer sources from 7 verified Indian suppliers, with S Kant Healthcare Limited accounting for 60.0% of imports.

TO THE Orer — Import Portfolio & Supplier Network

TO THE Orer import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to TO THE Orer?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
S Kant Healthcare Limited	$140.1K	4	60.0%
Hetero Labs Limited	$61.5K	4	26.3%
Indiana Ophthalmics Llp	$24.6K	12

What Formulations Does TO THE Orer Import?

Formulation	Value	Ships
Harmless medicines amodiaquine 150MG sulfadoxine pyrimethamine 500 25MG dispersible tablets supyra dispersible unit	$100.0K	2
Flusacort salmeterol 25 MCG + fluticasone propionate 250 MCG	$50.0K	1
Harmless medicines amodiaquine 75MG sulfadoxine pyrimethamine 250 12 5 MG dispersible tablet supyra dispersible	$40.1K	2
Torrox etoricoxib	$11.5K	3
Pharmaceutical harmless medicine for human use isotears plus 10ML,batch no d24d06 , oth as per	$7.1K	3
Pharmaceutical harmless medicine for human use safenac 10ML batch no: n24d19, oth as per	$6.1K	3
Pharmaceutical harmless medicine for human use timox eye drop 5 ML batch no d24c37 , oth as per	$6.0K	3
Pharmaceutical harmless medicine for human use tobramycin ophthalmic solution 5ML,batch no d24c38 , oth as per	$5.5K	3
Contain medicines harmless	$982	2
Harmless pharmaceutical medicines for human use batch no t24ol11b6 olaparib tablets 150MG	$489	1
Harmless pharmaceutical medicines for human use batch no n24309c n24287b methylprednisolone sodium succinate	$389	1
Harmless pharmaceutical medicines for human use batch no dr25032 tretinoin soft gelatin capsules 10 MG	$362	1
Harmless pharmaceutical medicines for human use batch no tr 2501 tropicamide 1 eye	$362	1
Modalert 200MG(modafinil)	$318	1
Harmless pharmaceutical medicines for human use batch no 25gb20c methylprednisolone sodium succinate injection USP	$308	1

TO THE Orer imports 184 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pyrimethamine	Antimalarial & Antiparasitic	$200.0K	4	0.4%	13
2	Sulfadoxine	Antimalarial & Antiparasitic	$200.0K	4	0.4%	12

TO THE Orer imports 2 pharmaceutical products across 1 categories into Gambia totaling $400.0K.

TO THE Orer — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

TO THE Orer is a pharmaceutical importer based in The Gambia, specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in the Gambian pharmaceutical distribution network, ensuring the availability of essential medications to meet the country's healthcare needs. While specific details about its headquarters and parent company are not publicly disclosed, TO THE Orer is recognized for its significant contributions to the importation and distribution of pharmaceutical products within The Gambia.

2Distribution Network

TO THE Orer's distribution network encompasses multiple warehouse locations strategically situated to facilitate efficient logistics and timely delivery of pharmaceutical products across The Gambia. The company's logistics capabilities are tailored to meet the demands of the Gambian market, ensuring that imported medications are readily accessible to healthcare providers nationwide. While the company primarily focuses on domestic distribution, its strategic positioning within the region suggests potential for broader geographic coverage in the future.

3Industry Role

In The Gambia's pharmaceutical supply chain, TO THE Orer functions as a primary wholesaler and importer. By sourcing finished pharmaceutical formulations from international suppliers, the company bridges the gap between global manufacturers and local healthcare providers, ensuring a steady supply of essential medications. This role is crucial in maintaining the availability of quality pharmaceuticals within the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — TO THE Orer

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

TO THE Orer's sourcing strategy exhibits a high degree of concentration, with a portfolio entirely focused on two products: Pyrimethamine and Sulfadoxine, each accounting for $200K in imports. This singular focus on antimalarial and antiparasitic medications indicates a strategic choice to specialize in a critical therapeutic area, addressing the prevalent health concerns in The Gambia. The consistent importation of these products from a select group of suppliers—S KANT HEALTHCARE LIMITED and HETERO LABS LIMITED—suggests a stable and reliable relationship, minimizing supply chain disruptions.

2Supply Chain Resilience

The resilience of TO THE Orer's supply chain is bolstered by its partnerships with reputable Indian pharmaceutical manufacturers, including S KANT HEALTHCARE LIMITED and HETERO LABS LIMITED. The company's focus on a limited number of suppliers allows for streamlined operations and quality control. However, this concentrated sourcing strategy may expose TO THE Orer to risks associated with supplier dependency. To mitigate potential disruptions, it would be prudent for the company to consider diversifying its supplier base and exploring alternative sourcing options.

3Strategic Implications

Importing Pharmaceuticals into Gambia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Gambia

1Regulatory Authority & Framework

The Medicines Control Agency (MCA) is the primary regulatory body overseeing the importation and distribution of pharmaceutical products in The Gambia. Established under the Medicines and Related Products Act of 2014, the MCA is responsible for market authorization, inspection, pharmacovigilance, import control, licensing, quality control, medicine advertisement and promotion, and clinical trials control. The agency ensures that all imported medicines meet international standards of quality, safety, and efficacy.

2Import Licensing & GMP

Importers in The Gambia are required to obtain an import permit from the MCA before bringing pharmaceutical products into the country. This process involves submitting an application that includes detailed product information and compliance with the MCA's guidelines. The MCA recognizes Good Manufacturing Practice (GMP) certifications from stringent regulatory authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications to facilitate the importation process. (mca.gm)

3Quality & Labeling

TO THE Orer — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

TO THE Orer's focus on antimalarial and antiparasitic medications aligns with the prevalent health challenges in The Gambia, where malaria remains a significant public health concern. By specializing in these therapeutic areas, the company addresses critical healthcare needs and positions itself as a key player in the country's pharmaceutical import sector. The consistent importation of Pyrimethamine and Sulfadoxine underscores the market demand for these treatments and TO THE Orer's commitment to meeting this demand.

2Sourcing Profile

TO THE Orer's sourcing strategy is centered on importing generic formulations from India, a country known for its robust pharmaceutical manufacturing sector. The company's preference for finished pharmaceutical formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a focus on ready-to-use products that can be directly distributed to healthcare providers. This approach streamlines the supply chain and ensures the availability of essential medications in The Gambia.

3Market Positioning

By specializing in antimalarial and antiparasitic medications, TO THE Orer serves a critical segment of The Gambia's pharmaceutical market, primarily supplying to hospitals, clinics, and healthcare providers involved in the treatment of malaria and related diseases. The company's strategic focus on these therapeutic areas positions it as a specialized wholesaler catering to the specific needs of the Gambian healthcare system.

Seller's Guide — How to Become a Supplier to TO THE Orer

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with TO THE Orer, given the company's established distribution network and focus on antimalarial and antiparasitic medications. Suppliers offering high-quality, GMP-certified products in these therapeutic areas can meet the existing demand and potentially expand TO THE Orer's product portfolio. Additionally, diversifying the supplier base could enhance supply chain resilience and mitigate risks associated with supplier dependency.

2Requirements & Qualifications

Indian exporters seeking to supply TO THE Orer and enter the Gambian market must ensure that their products are registered with the MCA and comply with the agency's import guidelines. This includes obtaining an import permit, providing samples for testing, and adhering to labeling requirements. Suppliers must also hold valid GMP certifications from recognized authorities such as the EU, WHO, or PIC/S to facilitate the importation process. (mca.gm)

3How to Approach

Frequently Asked Questions — TO THE Orer

What products does TO THE Orer import from India?

TO THE Orer imports 2 pharmaceutical products across 1 categories. Top imports: Pyrimethamine ($200.0K), Sulfadoxine ($200.0K).

Who supplies pharmaceuticals to TO THE Orer from India?

TO THE Orer sources from 7 verified Indian suppliers. The primary supplier is S Kant Healthcare Limited (60.0% of imports, $140.1K).

What is TO THE Orer's total pharmaceutical import value?

TO THE Orer's total pharmaceutical import value from India is $400.0K, based on 8 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does TO THE Orer focus on?

TO THE Orer imports across 1 categories. The largest: Antimalarial & Antiparasitic (100.0%).

Get Full TO THE Orer Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.